A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A, Marcheselli R, Marcheselli L, Alvarez I, Pozzi S, Ferri P, Lazzaro A, Fragasso A, Neri S, Baldini L, Carella AM, Angrilli F, Guariglia R, Buda G, Stelitano C, Sacchi S; Gruppo Italiano Studio Linfomi (GISL).
Bari A, et al. Among authors: sacchi s.
Acta Haematol. 2017;137(1):7-14. doi: 10.1159/000449052. Epub 2016 Nov 4.
Acta Haematol. 2017.
PMID: 27820922
Clinical Trial.